Background: In randomized trials, screening mammography has led to decreased mortality from breast cancer. However, the low positive predictive value of mammography (i.e., the proportion of patients with a positive test result who actually have breast cancer) results in a large number of unnecessary biopsies. We determined whether scintimammography with technetium99m-sestamibi is a useful supplemental diagnostic tool for women with nonpalpable breast abnormalities identified by conventional mammography. Methods: Scintimammography was performed preoperatively on 70 women who were 31-66 years of age (mean age and median age = 51 years). These women had nonpalpable breast abnormalities identified by conventional mammography; subsequently, a needlelocalization excisional biopsy of each suspicious lesion was performed. Scintimammographic images were interpreted independently by two nuclear medicine physicians who were blinded to all clinical and pathologic data, and an interobserver variation analysis was performed. Results: Interobserver variation analysis of the scintimammographic findings showed an agreement for breast diagnosis of 97% and a kappa coefficient of 0.90. Comparison of scintimammographic findings and histopathologic results revealed that the sensitivity (proportion of patients with breast cancer who had a positive test result), the specificity (proportion of patients without breast cancer who had a negative test result), the positive predictive value and the negative predictive value (pro-
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Randomized controlled clinical trials have demonstrated that mammography has a sensitivity (proportion of patients with breast cancer who have a positive test result) that ranges from 75% to 90% depending upon the characteristics of the screened population (14, 15) ; however, the sensitivity has been reported to be reduced by 10% or more for women aged 40-49 years and for women with dense breasts (15, 16) . Although mammography is the most effective test to detect early breast carcinoma, only a small fraction of abnormalities that are detected by screening mammography and subsequently subjected to biopsy examination result in a diagnosis of cancer. The low positive predictive value of mammography means that a large proportion of breast biopsies will be performed on lesions or other mammographic abnormalities that turn out to be benign (6, 17, 18) . There is a critical need to develop an accurate, noninvasive imaging technique that will allow a reduction in the number of surgical biopsies that are performed.
Scintimammography, using technetium-99m-sestamibi (Tc-99m sestamibi), has been demonstrated to play a role in the evaluation of primary breast carcinoma. A previous study at our institution (19) has shown that, for diagnosis of breast cancer in a cohort of patients with palpable as well as nonpalpable breast masses, scintimammography has a sensitivity of 93.7, a specificity (proportion of patients without breast cancer who had a negative test result) of 87.8%, a positive predictive value (proportion of patients with a positive test result who actually have breast cancer) of 76.9%, and a negative predictive value (proportion of patients with a negative test result who actually do not have breast cancer) of 97%. A report (20) has shown that scintimammography is 93% sensitive to detect breast cancer in patients with palpable breast lesions.
Based on these findings, scintimammography may complement mammography by improving the low positive predictive value in the detection of early breast carcinoma in patients with nonpalpable lesions. Thus, the objective of this study was to determine the usefulness of Tc99m sestamibi scintimammography in the analysis of nonpalpable breast lesions or other abnormalities detected by mammography.
Patients and Methods
Research imaging with scintimammography was begun at Harbor-UCLA Medical Center in April 1992. The study protocol was reviewed and approved by the Institutional Review Board and The Human Subjects Committee of the Harbor-UCLA Research and Educational Institute. We have prospectively collected a large database of patients who were subjected to scintimammography and to subsequent histopathologic assessment. This report represents a retrospective review of patients with nonpalpable mammographic abnormalities. From May 1992 through December 1996, we analyzed 70 consecutive patients who were 31-66 years of age (mean age and median age ‫ס‬ 51 years), who had nonpalpable breast masses, and who volunteered to have a preoperative scintimammogram. These patients were selected on the basis of history, physical examination, and mammography. The patients were referred for biopsy examination on the basis of mammographic findings only; scintimammography was excluded from the decision-making process. All 70 patients had an abnormal mammographic examination and no palpable breast mass. Mammography identified 45 masses, 14 microcalcifications, and 11 asymmetrical densities. The mammographic findings were categorized according to the Breast Imaging Reporting and Data System (BI-RADS) from the American College of Radiology (21) and were as follows: two patients in category 3 (probably benign), 63 patients in category 4 (intermediate or suspicious for malignancy), and five patients in category 5 (highly suspicious for malignancy). The mammographic findings in the patients with infiltrating ductal carcinoma were as follows: two spiculated masses (category 5) and three indeterminate masses (category 4). The mammographic findings in the four patients with ductal carcinoma in situ (DCIS) showed the following: two with indeterminate microcalcifications without an associated mass (category 4), one with probably benign microcalcifications (category 3), and one with an indeterminate mass (category 4).
A mammographically guided breast biopsy was ordered by the primary physician when a patient was found to have a breast abnormality on a screening mammogram. However, prior to the biopsy, scintimammography was performed on each patient after intravenous injection of 20 mCi (740 MBq) of the isotopic tracer Tc-99m sestamibi (Cardiolite; Dupont Merck Pharmaceutical, North Billerica, MA) in the arm contralateral to the mammographic abnormality. A rectangular head camera (Sophy DSX; Sopha Medical Systems, Columbia, MD) with a highresolution collimator was used, and planar images were obtained with a 10% window centered at 140 KeV. Imaging was performed with the patient in the prone position on a plastic overlay table (Bodfish Research and Design, Bodfish, CA), allowing the breast being imaged to hang freely and, thus, independent of the imaging table. Ten-minute, lateral image data acquisitions of each breast were performed beginning 5 minutes after injection of the isotopic tracer. A 10-minute upright anterior planar image was obtained with the patient's arms above her head. The whole-body radiation dose was approximately 0.3 rad (3 mGy); the breast received minimal radiation, with the dose estimated to be approximately 0.13 rad. At the completion of the study, images were interpreted independently by two experienced nuclear medicine physicians who were blinded with respect to the patients' identities and to the pathologic data. The physicians interpreted scintimammographic images of the breast only and not of the axillary region. Bilateral-diffuse, symmetric, poor uptake of the tracer in both breasts was considered a negative result. Focal areas of increased uptake of the tracer were interpreted as a positive result (i.e., suspicious for malignancy). Next, mammographically guided excisional biopsies were performed on the patients in the standard fashion (22) , and specimen mammography was performed to confirm the presence of the lesion depicted in the preoperative mammogram. Subsequently, the histologic characteristics of the specimens were evaluated by a pathologist, and the scintimammographic readings were correlated with the histologic features.
Statistics
Statistical analysis with two-way tables and kappa measure of reliability (23) was done to compare interobserver variability between the two nuclear medicine physicians, each of whom was blinded to the analysis of the other, in the interpretations of the scintimammographic data. Screening statistics, including Fleiss quadratic confidence intervals (CIs), were calculated (23) . BMPD Statistical Software (Los Angeles, CA), version 7.0, was used for these calculations.
Results
Seventy patients were included in the analysis. The mean age of the patient population was 51 years (95% CI ‫ס‬ 49 years-53 years). Sixty-one patients (87%) had lesions with benign histology, and nine (13%) had breast cancer. Histologic assessments of the mammographic abnormalities are depicted in Table 1 . Five cases of breast cancer were detected as a focal uptake of tracer on the scintimammograms. The sizes of the lesions ranged from 1.5 cm-3.7 cm in the longest dimension. Four lesions had no evidence of focal uptake (false negatives), and they ranged in the longest dimension from 0.5 cm-3 cm. Overall, scintimammography in this cohort of patients showed a sensitivity and a specificity of 56% (95% CI ‫ס‬ 23%-85%) and 87% (95% CI ‫ס‬ 75%-94%). The positive predictive value was 38% (95% CI ‫ס‬ 15%-68%), and the negative predictive value was 93% (95% CI ‫ס‬ 82%-98%) ( Table 2) .
As noted above, four false-negative abnormalities were detected by scintimammography (false-negative rate ‫ס‬ 44%). Two of the false-negative abnormalities had comedo-type DCIS, and the remaining two were determined to be infiltrating adenocarcinoma with a comedotype component. On the other hand, there were eight false-positive scintimammograms, none of which had common histologic features (Table 3) .
The independent, blinded interpretations of the scintimammograms by the two nuclear medicine physicians were found to have an agreement of 97% and a kappa coefficient 0.90 (95% CI ‫ס‬ 0.67-0.93) ( Table 4 ). In the two cases of disagreement, the final accepted interpretation was reached by a third radiologist, who also worked independently and was blinded to the mammographic and pathologic findings.
Discussion
During the last several decades, mammography has proven to be the single most reliable method to detect breast abnormalities (24) . The only means of excluding the possibility of breast cancer in patients with nonpalpable suspicious mammographic masses is to perform a biopsy and analyze specimens. However, the frequency of negative findings in needle-localized biopsy specimens varies from 82% to 87% (6,18) . Therefore, the majority of patients undergo a biopsy procedure unnecessarily. Given this result, the development of a complementary noninvasive test to improve the specificity of mammography is warranted.
Previous studies using scintimammography (19, (25) (26) (27) (28) have found that the technique has a high sensitivity (i.e., 84%-94%) for the detection of palpable breast masses. Palmedo et al. (27) reported that scintimammography may improve the diagnostic accuracy of mammography and, thus, decrease the number of breast biopsies performed on benign lesions.
Our results are consistent with previous reports showing that the high specificity and negative predictive value of scintimammography improve the low yield of breast biopsies for mammographically suspicious lesions (29) . However, the sensitivity of scintimammography for patients with nonpalpable lesions is low compared with that found for patients with palpable breast masses. If scintimammography were used as a second screening modality in patients with mammographically suspicious lesions, almost half of the mammographically detected, early breast cancers in the population we studied would have been dismissed. In patients with a mammogram suspicious for cancer and positive scintimammographic findings, the high specificity (87%) of scintimammography and, thus, the higher likelihood of harboring a breast cancer may warrant a wider biopsy to obtain negative margins.
Among the four false-negative cases, the common factor of intraductal comedotype features with (two patients) or without (two patients) an invasive component was identified. This finding did not seem to be associated with lesion size, since the lesions varied from 0.5 cm to 3 cm, suggesting that the biology of DCIS or the component of necrosis in comedotype DCIS may have less affinity for Tc-99m sestamibi. Other work at Harbor-UCLA Medical Center has shown that there is a relationship between the degree of Tc-99m sestamibi uptake in breast lesions and the degree of desmoplasia (30) . Thus, in DCIS, where the degree of desmoplasia and cellular atypia is minimal, technetium-99m sestamibi uptake may be low. Unfortunately, the low sensitivity of scintimammography in this group, coupled with the low prevalence of cancer (a result of the poor positive predictive value of mammography) leads to a very uncertain positive predictive value for scintimammography.
On the basis of these data, scintimammography, at its current stage of development, is not an appropriate second screening test to determine whether or not a patient with an abnormal mammogram and a nonpalpable breast lesion should have a breast biopsy. However, when positive findings are obtained, scintimammography may help surgeons plan their surgical approach to obtain a negative margin in women who require a lumpectomy. Furthermore, scintimammography may play a role in the evaluation of patients in whom prior breast surgery, radiotherapy, or dense breasts make mammography difficult to interpret (31). ‫ס‬ 23%-85%); specificity ‫ס‬ 87% (95% CI ‫ס‬ 75%-94%); positive predictive value ‫ס‬ 38% (95% CI ‫ס‬ 15%-68%); negative predictive value ‫ס‬ 93% (95% CI ‫ס‬ 82%-98%).
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†Tc-99m-sestamibi ‫ס‬ technetium-99m-sestamibi (an isotopic tracer). *Uptake refers to uptake of the tracer technetium99m-sestamibi.
†Interobserver agreement ‫ס‬ 97%; kappa measure of reliability ‫ס‬ 0.90 (95% confidence interval of kappa ‫ס‬ 0.67-0.93).
